Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 1
1994 1
1997 1
2000 3
2001 5
2002 6
2003 7
2004 8
2005 14
2006 16
2007 20
2008 24
2009 28
2010 39
2011 41
2012 51
2013 73
2014 82
2015 103
2016 104
2017 88
2018 132
2019 180
2020 182
2021 247
2022 272
2023 228
2024 86

Text availability

Article attribute

Article type

Publication date

Search Results

1,735 results

Results by year

Filters applied: . Clear all
Page 1
Cutaneous T-cell lymphoma following dupilumab use: a systematic review.
Park A, Wong L, Lang A, Kraus C, Anderson N, Elsensohn A. Park A, et al. Int J Dermatol. 2023 Jul;62(7):862-876. doi: 10.1111/ijd.16388. Epub 2022 Sep 8. Int J Dermatol. 2023. PMID: 36073768 Review.
In recent years, studies have associated dupilumab with unmasking or progression of cutaneous T-cell lymphoma (CTCL). The objective of this study was to synthesize reported cases of CTCL in the setting of dupilumab use. ...
In recent years, studies have associated dupilumab with unmasking or progression of cutaneous T-cell lymphoma (CTCL). The objective o …
Comparison of Allogeneic Stem Cell Transplant and Autologous Stem Cell Transplant in Refractory or Relapsed Peripheral T-Cell Lymphoma: A Systematic Review and Meta-analysis.
Du J, Yu D, Han X, Zhu L, Huang Z. Du J, et al. JAMA Netw Open. 2021 May 3;4(5):e219807. doi: 10.1001/jamanetworkopen.2021.9807. JAMA Netw Open. 2021. PMID: 34042995 Free PMC article.
IMPORTANCE: Hematopoietic stem cell transplant (HSCT) is an advisable option for refractory or relapsed peripheral T-cell lymphoma (R/R-PTCL), but whether allogeneic HSCT or autologous HSCT is more beneficial is unknown. ...DATA SOURCES: A systematic search of the PubMed, …
IMPORTANCE: Hematopoietic stem cell transplant (HSCT) is an advisable option for refractory or relapsed peripheral T-cell lymphoma (R …
Toxicity and efficacy of CAR T-cell therapy in primary and secondary CNS lymphoma: a meta-analysis of 128 patients.
Cook MR, Dorris CS, Makambi KH, Luo Y, Munshi PN, Donato M, Rowley S, Saad A, Goy A, Dunleavy K, Ali A. Cook MR, et al. Blood Adv. 2023 Jan 10;7(1):32-39. doi: 10.1182/bloodadvances.2022008525. Blood Adv. 2023. PMID: 36260735 Free PMC article.
Relapsed/refractory primary central nervous system lymphoma (PCNSL) and secondary central nervous system lymphoma (SCNSL) are associated with short survival and represent an unmet need, requiring novel effective strategies. ...Encouraging efficacy was demonstrated i …
Relapsed/refractory primary central nervous system lymphoma (PCNSL) and secondary central nervous system lymphoma (SCNSL) are …
Topical calcineurin inhibitors and risk of lymphoma: a systematic review and meta-analysis.
Wu PC, Huang IH, Liu CW, Huang YC. Wu PC, et al. J Dtsch Dermatol Ges. 2021 Sep;19(9):1265-1269. doi: 10.1111/ddg.14527. Epub 2021 Aug 13. J Dtsch Dermatol Ges. 2021. PMID: 34390192 Review.
To assess the outcome of TCI-related risk of lymphoma, analysis of cohort studies comparing the incidence of lymphoma with and without treatment with TCIs was performed. ...Additionally, subgroup analyses showed both tacrolimus (RR 1.89; 95 % CI 1.53-2.32) and pimec …
To assess the outcome of TCI-related risk of lymphoma, analysis of cohort studies comparing the incidence of lymphoma with and …
Primary immunodeficiencies and lymphoma: a systematic review of literature.
Herber M, Mertz P, Dieudonné Y, Guffroy B, Jung S, Gies V, Korganow AS, Guffroy A. Herber M, et al. Leuk Lymphoma. 2020 Feb;61(2):274-284. doi: 10.1080/10428194.2019.1672056. Epub 2019 Oct 3. Leuk Lymphoma. 2020. PMID: 31580160
The most prevalent lymphoma was diffuse large B-cell lymphoma (33.5%). Epstein-Barr Virus-driven lymphomas were mostly observed in innate immunodeficiencies (when reported). ...Our detailed analysis of the literature provides a landscape of lymphoma' …
The most prevalent lymphoma was diffuse large B-cell lymphoma (33.5%). Epstein-Barr Virus-driven lymphomas were mostly …
CAR-T cell therapy for patients with hematological malignancies. A systematic review.
Pasqui DM, Latorraca CDOC, Pacheco RL, Riera R. Pasqui DM, et al. Eur J Haematol. 2022 Dec;109(6):601-618. doi: 10.1111/ejh.13851. Epub 2022 Sep 18. Eur J Haematol. 2022. PMID: 36018500 Review.
The available results are from studies assessing axicabtagene, lisocabtagene, and tisagenlecleucel for patients with B cell lymphoma, and the certainty of evidence ranged from very low to low for survival and progression-related outcome and for safety outcomes. Additionall …
The available results are from studies assessing axicabtagene, lisocabtagene, and tisagenlecleucel for patients with B cell lymphoma, …
Anxiety prevalence in lymphoma: A systematic review and meta-analysis.
Vargas-Román K, Díaz-Rodríguez CL, Cañadas-De la Fuente GA, Gómez-Urquiza JL, Ariza T, De la Fuente-Solana EI. Vargas-Román K, et al. Health Psychol. 2020 Jul;39(7):580-588. doi: 10.1037/hea0000869. Epub 2020 Mar 26. Health Psychol. 2020. PMID: 32212767
OBJECTIVE: Hodgkin and non-Hodgkin lymphoma patients are at high risk of experiencing anxiety because the clinical processes and therapies they undergo produce strong adverse effects. ...The I2 for the heterogeneity analysis was 92.6%. CONCLUSIONS: Hodgkin and non-Hodgkin …
OBJECTIVE: Hodgkin and non-Hodgkin lymphoma patients are at high risk of experiencing anxiety because the clinical processes and ther …
A systematic review and meta-analysis of occupational exposures and risk of follicular lymphoma.
Odutola MK, Benke G, Fritschi L, Giles GG, van Leeuwen MT, Vajdic CM. Odutola MK, et al. Environ Res. 2021 Jun;197:110887. doi: 10.1016/j.envres.2021.110887. Epub 2021 Feb 17. Environ Res. 2021. PMID: 33607095 Review.
BACKGROUND: The etiology of follicular lymphoma (FL), a common non-Hodgkin lymphoma subtype, is largely unknown. ...
BACKGROUND: The etiology of follicular lymphoma (FL), a common non-Hodgkin lymphoma subtype, is largely unknown. ...
Challenges and opportunities in primary CNS lymphoma: A systematic review.
Kerbauy MN, Moraes FY, Lok BH, Ma J, Kerbauy LN, Spratt DE, Santos FP, Perini GF, Berlin A, Chung C, Hamerschlak N, Yahalom J. Kerbauy MN, et al. Radiother Oncol. 2017 Mar;122(3):352-361. doi: 10.1016/j.radonc.2016.12.033. Epub 2017 Jan 16. Radiother Oncol. 2017. PMID: 28104300 Review.
BACKGROUND: Historically, high-dose methotrexate (HD-MTX) plus consolidation chemotherapy and/or whole brain radiotherapy (WBRT) has been the gold standard on Primary Central Nervous System Lymphoma (PCNSL) management. We sought to examine and summarize the data, on clinic …
BACKGROUND: Historically, high-dose methotrexate (HD-MTX) plus consolidation chemotherapy and/or whole brain radiotherapy (WBRT) has been th …
Clinical efficacy and safety of subcutaneous rituximab in non-Hodgkin lymphoma: a systematic literature review and meta-analysis.
Si T, Ma X, Zhu W, Zhou Y. Si T, et al. Hematology. 2023 Dec;28(1):2284047. doi: 10.1080/16078454.2023.2284047. Epub 2023 Nov 27. Hematology. 2023. PMID: 38010876 Review.
OBJECTIVES: The role of subcutaneous (SC) rituximab in the efficacy and safety to non-Hodgkin lymphoma (NHL) is not clear enough. The purpose of this study was to conduct a systematic review and meta-analysis, to assess the efficacy and safety of subcutaneous rituximab to …
OBJECTIVES: The role of subcutaneous (SC) rituximab in the efficacy and safety to non-Hodgkin lymphoma (NHL) is not clear enough. The …
1,735 results